GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Cyclically Adjusted PB Ratio

Vaxart (STU:NB11) Cyclically Adjusted PB Ratio : 0.08 (As of Jun. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Vaxart Cyclically Adjusted PB Ratio?

As of today (2024-06-21), Vaxart's current share price is €0.58. Vaxart's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €7.42. Vaxart's Cyclically Adjusted PB Ratio for today is 0.08.

The historical rank and industry rank for Vaxart's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:NB11' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.17   Max: 0.51
Current: 0.09

During the past years, Vaxart's highest Cyclically Adjusted PB Ratio was 0.51. The lowest was 0.01. And the median was 0.17.

STU:NB11's Cyclically Adjusted PB Ratio is ranked better than
89.06% of 658 companies
in the Biotechnology industry
Industry Median: 1.67 vs STU:NB11: 0.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vaxart's adjusted book value per share data for the three months ended in Mar. 2024 was €0.290. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €7.42 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vaxart Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Vaxart's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Cyclically Adjusted PB Ratio Chart

Vaxart Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.22 0.39 0.08 0.06

Vaxart Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.07 0.08 0.06 0.16

Competitive Comparison of Vaxart's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted PB Ratio falls into.



Vaxart Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vaxart's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.58/7.42
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Vaxart's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.29/131.7762*131.7762
=0.290

Current CPI (Mar. 2024) = 131.7762.

Vaxart Quarterly Data

Book Value per Share CPI Adj_Book
201406 20.043 100.560 26.265
201409 18.944 100.428 24.857
201412 20.942 99.070 27.856
201503 23.584 99.621 31.196
201506 17.643 100.684 23.091
201509 16.108 100.392 21.144
201512 15.028 99.792 19.845
201603 13.472 100.470 17.670
201606 11.705 101.688 15.168
201609 9.284 101.861 12.011
201612 7.556 101.863 9.775
201703 6.440 102.862 8.250
201706 4.737 103.349 6.040
201709 3.319 104.136 4.200
201712 2.597 104.011 3.290
201803 3.533 105.290 4.422
201806 2.679 106.317 3.321
201809 1.919 106.507 2.374
201812 1.383 105.998 1.719
201903 1.334 107.251 1.639
201906 0.888 108.070 1.083
201909 0.371 108.329 0.451
201912 0.242 108.420 0.294
202003 0.393 108.902 0.476
202006 0.372 108.767 0.451
202009 1.021 109.815 1.225
202012 0.920 109.897 1.103
202103 1.255 111.754 1.480
202106 1.350 114.631 1.552
202109 1.390 115.734 1.583
202112 1.321 117.630 1.480
202203 1.200 121.301 1.304
202206 1.071 125.017 1.129
202209 0.963 125.227 1.013
202212 0.778 125.222 0.819
202303 0.618 127.348 0.639
202306 0.517 128.729 0.529
202309 0.441 129.860 0.448
202312 0.345 129.419 0.351
202403 0.290 131.776 0.290

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vaxart  (STU:NB11) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vaxart Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Vaxart's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxart (STU:NB11) Business Description

Industry
Traded in Other Exchanges
Address
170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart (STU:NB11) Headlines

No Headlines